DK2019683T4 - Indgivelse af vækstfaktorer til behandling af CNS-lidelser - Google Patents
Indgivelse af vækstfaktorer til behandling af CNS-lidelser Download PDFInfo
- Publication number
- DK2019683T4 DK2019683T4 DK07761286.9T DK07761286T DK2019683T4 DK 2019683 T4 DK2019683 T4 DK 2019683T4 DK 07761286 T DK07761286 T DK 07761286T DK 2019683 T4 DK2019683 T4 DK 2019683T4
- Authority
- DK
- Denmark
- Prior art keywords
- administration
- treatment
- growth factors
- cns disorders
- cns
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0461—Dispersions, colloids, emulsions or suspensions
- A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
- A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
- A61K51/1234—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79501206P | 2006-04-25 | 2006-04-25 | |
PCT/US2007/067423 WO2007127803A2 (en) | 2006-04-25 | 2007-04-25 | Administration of growth factors for the treatment of cns disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
DK2019683T3 DK2019683T3 (da) | 2017-03-20 |
DK2019683T4 true DK2019683T4 (da) | 2022-08-29 |
Family
ID=38656355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07761286.9T DK2019683T4 (da) | 2006-04-25 | 2007-04-25 | Indgivelse af vækstfaktorer til behandling af CNS-lidelser |
Country Status (12)
Country | Link |
---|---|
US (5) | US7922999B2 (da) |
EP (1) | EP2019683B2 (da) |
JP (2) | JP6105187B2 (da) |
AU (1) | AU2007244826B2 (da) |
BR (1) | BRPI0710800A2 (da) |
DK (1) | DK2019683T4 (da) |
ES (1) | ES2618787T5 (da) |
HU (1) | HUE030903T2 (da) |
PL (1) | PL2019683T5 (da) |
PT (1) | PT2019683T (da) |
SI (1) | SI2019683T2 (da) |
WO (1) | WO2007127803A2 (da) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
US7276580B2 (en) | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
ES2479942T3 (es) | 2003-04-18 | 2014-07-25 | Biogen Idec Ma Inc. | Neublastina glucosilada conjugada con polímero |
EP2238983B1 (en) * | 2004-08-19 | 2014-07-23 | Biogen Idec MA Inc. | Neublastin variants |
EP1784203B1 (en) | 2004-08-19 | 2010-06-30 | Biogen Idec MA Inc. | Refolding transforming growth factor beta family proteins |
AU2005294247B2 (en) * | 2004-10-05 | 2011-08-11 | Genzyme Corporation | Stepped cannula |
EP1928557B1 (en) | 2005-08-23 | 2018-06-06 | The Regents of The University of California | Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery |
TWI501774B (zh) * | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
EP1872790A1 (en) * | 2006-06-26 | 2008-01-02 | DeveloGen Aktiengesellschaft | New formulation for increasing bioavailability of neurturin |
EP2142205B1 (en) | 2007-05-01 | 2014-04-02 | Biogen Idec MA Inc. | Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow |
US20090130017A1 (en) * | 2007-11-19 | 2009-05-21 | Searete Llc | Targeted short-lived drug delivery |
US20100021422A1 (en) * | 2008-03-05 | 2010-01-28 | Regenerative Research Foundation | Methods and compositions for delivery of exogenous factors to nervous system sites |
EP3417701B1 (en) | 2009-10-06 | 2021-12-15 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
PL2558154T3 (pl) | 2010-04-16 | 2020-11-30 | Clearpoint Neuro, Inc. | Systemy chirurgiczne MRI zawierające kaniule chirurgiczne kompatybilne z MRI do transferu substancji do i/lub od pacjenta |
US9045751B2 (en) | 2010-04-28 | 2015-06-02 | The Regents Of The University Of California | Modified small activating RNA molecules and methods of use |
EP4202040A1 (en) | 2010-07-01 | 2023-06-28 | Regenerative Research Foundation | Methods for culturing undifferentiated cells using sustained release compositions |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
CN103619879A (zh) | 2010-12-01 | 2014-03-05 | 奥尔德生物控股有限责任公司 | 抗ngf组合物及其用途 |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
GB201101167D0 (en) * | 2011-01-22 | 2011-03-09 | Renishaw Plc | Convection enhanced delivery apparatus and method |
DK2675271T3 (da) | 2011-02-15 | 2018-08-27 | Regeneron Pharma | Humaniserede m-csf-mus |
DK2839013T3 (da) | 2012-04-18 | 2020-09-14 | Univ Leland Stanford Junior | Ikke-disruptiv-gen-targetering |
DK3241902T3 (da) | 2012-05-25 | 2018-05-07 | Univ California | Fremgangsmåder og sammensætninger til rna-rettet target-dna-modificering og til rna-rettet modulering af transkription |
IN2015DN02032A (da) | 2012-09-07 | 2015-08-14 | Univ Yale | |
PT3308641T (pt) | 2012-11-05 | 2019-10-24 | Univ Yale | Roedor imunodeficiente geneticamente modificado e métodos de utilização do mesmo. |
CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
WO2014202833A1 (en) * | 2013-06-18 | 2014-12-24 | University Of Helsinki | Treatment of neuronal injuries |
US9891296B2 (en) | 2013-09-13 | 2018-02-13 | MRI Interventions, Inc. | Intrabody fluid transfer devices, systems and methods |
SG10201802231RA (en) | 2013-09-19 | 2018-05-30 | Univ Leland Stanford Junior | Methods and compositions for producing hepatocyte-like cells |
US9932607B2 (en) | 2013-11-15 | 2018-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Site-specific integration of transgenes into human cells |
AU2014350051A1 (en) | 2013-11-18 | 2016-07-07 | Crispr Therapeutics Ag | CRISPR-Cas system materials and methods |
WO2015089277A1 (en) | 2013-12-12 | 2015-06-18 | The Regents Of The University Of California | Methods and compositions for modifying a single stranded target nucleic acid |
CA2939847C (en) | 2014-03-21 | 2023-09-05 | The Board Of Trustees Of The Leland Stanford Junior University | Genome editing without nucleases |
SG10201809739QA (en) | 2014-05-02 | 2018-12-28 | Genzyme Corp | Aav vectors for retinal and cns gene therapy |
KR102574155B1 (ko) | 2014-05-19 | 2023-09-05 | 리제너론 파마슈티칼스 인코포레이티드 | 인간 epo를 발현하는 유전자 변형된 비-인간 동물 |
SG10202007103TA (en) | 2014-11-05 | 2020-09-29 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
US10377818B2 (en) | 2015-01-30 | 2019-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating glioma |
EP4219728A3 (en) | 2015-02-10 | 2023-08-23 | Genzyme Corporation | Enhanced delivery of viral particles to the striatum and cortex |
CA2979065A1 (en) | 2015-03-24 | 2016-09-29 | The Regents Of The University Of California | Adeno-associated virus variants and methods of use thereof |
US10123518B2 (en) | 2015-04-13 | 2018-11-13 | Regeneron Pharmaceuticals, Inc | Genetically modified non-human animals and methods of use thereof |
EA037993B1 (ru) | 2015-09-23 | 2021-06-21 | Сангамо Терапьютикс, Инк. | Репрессоры htt и их применение |
EP3353297A1 (en) | 2015-09-24 | 2018-08-01 | Crispr Therapeutics AG | Novel family of rna-programmable endonucleases and their uses in genome editing and other applications |
WO2017142698A1 (en) | 2016-02-17 | 2017-08-24 | MRI Interventions, Inc. | Intrabody surgical fluid transfer assemblies with adjustable exposed cannula to needle tip length, related systems and methods |
US20200291368A1 (en) | 2016-03-11 | 2020-09-17 | Wageningen Universiteit | Improved CRISPR-Cpf1 Genome Editing Tool |
US20200291369A1 (en) | 2016-03-11 | 2020-09-17 | Erasmus University Medical Center Rotterdam | Improved CRISPR-Cas9 Genome Editing Tool |
US11298041B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
US11332713B2 (en) | 2016-11-16 | 2022-05-17 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
US11504389B2 (en) | 2016-12-01 | 2022-11-22 | Sangamo Therapeutics, Inc. | Tau modulators and methods and compositions for delivery thereof |
EP3554546A4 (en) | 2016-12-14 | 2021-04-14 | Ligandal, Inc. | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF NUCLEIC ACID AND PROTEIN PAYLOADS |
JP7356356B2 (ja) * | 2017-05-25 | 2023-10-04 | ニューヨーク ステム セル ファウンデーション インコーポレイテッド | 前脳基底部コリン作動性神経細胞(bfcn)を生成するための方法および組成物 |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
CA3070087A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
MA50579A (fr) | 2017-11-09 | 2020-09-16 | Crispr Therapeutics Ag | Systèmes crispr/cas ou crispr/cpf1 à auto-inactivation (sin) et leurs utilisations |
AU2018386301A1 (en) | 2017-12-14 | 2020-06-18 | Bayer Healthcare Llc | Novel RNA-programmable endonuclease systems and their use in genome editing and other applications |
WO2019123414A1 (en) | 2017-12-22 | 2019-06-27 | Straximm Llp | Engineered viruses expressing cyclic gmp-amp synthase |
CA3093915A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
US20190284553A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
US20210054353A1 (en) | 2018-03-19 | 2021-02-25 | Crispr Therapeutics Ag | Novel rna-programmable endonuclease systems and uses thereof |
US11253237B2 (en) | 2018-05-09 | 2022-02-22 | Clearpoint Neuro, Inc. | MRI compatible intrabody fluid transfer systems and related devices and methods |
US11022664B2 (en) | 2018-05-09 | 2021-06-01 | Clearpoint Neuro, Inc. | MRI compatible intrabody fluid transfer systems and related devices and methods |
US20190350898A1 (en) * | 2018-05-18 | 2019-11-21 | Neurotrope Bioscience, Inc. | Methods and compositions for treatment of alzheimer's disease |
CN109381488A (zh) * | 2018-12-22 | 2019-02-26 | 包桂荣 | 癫痫病的外用药剂及制备方法 |
WO2020152607A1 (en) | 2019-01-22 | 2020-07-30 | St. Jude Children's Research Hospital | Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration |
US20220145330A1 (en) | 2019-02-10 | 2022-05-12 | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads | Modified mitochondrion and methods of use thereof |
WO2020209959A1 (en) | 2019-03-08 | 2020-10-15 | Crispr Therapeutics Ag | Nucleobase-editing fusion protein systems, compositions, and uses thereof |
CA3132630A1 (en) | 2019-03-12 | 2020-09-17 | Crispr Therapeutics Ag | Novel high fidelity rna-programmable endonuclease systems and uses thereof |
CN110192859B (zh) * | 2019-05-05 | 2020-05-19 | 兰月 | 一种磁共振测量人脑类淋巴通路清除效率的方法 |
EP3966327A1 (en) | 2019-05-08 | 2022-03-16 | Vertex Pharmaceuticals Incorporated | Crispr/cas all-in-two vector systems for treatment of dmd |
US11684750B2 (en) | 2019-10-08 | 2023-06-27 | Clearpoint Neuro, Inc. | Extension tube assembly and related medical fluid transfer systems and methods |
WO2022018638A1 (en) | 2020-07-21 | 2022-01-27 | Crispr Therapeutics Ag | Genome-editing compositions and methods to modulate faah for treatment of neurological disorders |
EP4101928A1 (en) | 2021-06-11 | 2022-12-14 | Bayer AG | Type v rna programmable endonuclease systems |
BR112023023768A2 (pt) | 2021-06-11 | 2024-02-27 | Bayer Ag | Sistemas de endonucleases programáveis por rna tipo v |
EP4144841A1 (en) | 2021-09-07 | 2023-03-08 | Bayer AG | Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof |
WO2023118068A1 (en) | 2021-12-23 | 2023-06-29 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
WO2023237587A1 (en) | 2022-06-10 | 2023-12-14 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US37410A (en) | 1863-01-13 | Improvement in machines for seaming metal roofing | ||
US5843473A (en) * | 1989-10-20 | 1998-12-01 | Sequus Pharmaceuticals, Inc. | Method of treatment of infected tissues |
ATE275197T1 (de) | 1991-09-20 | 2004-09-15 | Amgen Inc | Glial neurotrophe faktor |
AU7676894A (en) * | 1993-08-27 | 1995-03-21 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Convection-enhanced drug delivery |
FR2717824B1 (fr) * | 1994-03-25 | 1996-04-26 | Rhone Poulenc Rorer Sa | Virus recombinants, préparation et utilisation en thérapie génique. |
ZA952485B (en) * | 1994-03-28 | 1995-12-15 | Nycomed Imaging As | Liposomes |
EP0755454B1 (en) * | 1994-04-13 | 2008-02-13 | The Rockefeller University | Aav-mediated delivery of dna to cells of the nervous system |
US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US5733875A (en) * | 1994-11-15 | 1998-03-31 | Amgen Inc. | Methods of using GDNF as a neuroprotective agent |
FR2727867B1 (fr) * | 1994-12-13 | 1997-01-31 | Rhone Poulenc Rorer Sa | Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux |
US5830857A (en) * | 1995-07-14 | 1998-11-03 | Amgen Inc. | Method of treating epilepsy |
US5731284A (en) * | 1995-09-28 | 1998-03-24 | Amgen Inc. | Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product |
US5741778A (en) * | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
WO1998020857A1 (en) * | 1996-11-12 | 1998-05-22 | The Regents Of The University Of California | Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery |
US6042579A (en) * | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
WO1999012560A1 (en) * | 1997-09-09 | 1999-03-18 | Creative Biomolecules, Inc. | Synergistic effects of op/bmp morphogens and gdnf/ngf neurotrophic factors |
DE69821629T2 (de) * | 1997-09-19 | 2005-01-13 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Kombinationen von Cytokinen mit neurotroper Aktivität |
US7157435B2 (en) * | 1998-04-15 | 2007-01-02 | The Regents Of The University Of California | Methods for modulation of the effects of aging on the primate brain |
US6815431B2 (en) * | 1998-04-15 | 2004-11-09 | Regents Of The University Of California | Methods for therapy of neurodegenerative disease of the brain |
US6451306B1 (en) * | 1998-04-15 | 2002-09-17 | The Regents Of The University Of California | Methods for therapy of neurodegenerative disease of the brain |
ES2324540T3 (es) * | 1998-05-27 | 2009-08-10 | Genzyme Corporation | Vectores aav para la fabricacion de medicamentos para la administracion potenciada por conveccion. |
US7018628B1 (en) * | 1998-07-24 | 2006-03-28 | Aventis Pharma S.A. | Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates |
US6800281B2 (en) * | 2000-11-09 | 2004-10-05 | Oxford Biomedica (Uk) Limited | Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases |
CA2327208A1 (en) * | 2000-11-30 | 2002-05-30 | The Government Of The United States Of America | Methods of increasing distribution of therapeutic agents |
US7182944B2 (en) * | 2001-04-25 | 2007-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of increasing distribution of nucleic acids |
IL162838A0 (en) * | 2002-01-04 | 2005-11-20 | Univ Rockefeller | Compositions and methods for prevention and treatment peptide-of amyloid- related disorders |
CA2499573A1 (en) * | 2002-09-24 | 2004-04-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for convection enhanced delivery of therapeutic agents |
US20040209810A1 (en) * | 2003-02-24 | 2004-10-21 | Gill Steven S. | Method of treating Parkinson's disease in humans by intraputaminal infusion of glial cell-line derived neurotrophic factor |
US8946151B2 (en) * | 2003-02-24 | 2015-02-03 | Northern Bristol N.H.S. Trust Frenchay Hospital | Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen |
US20050112065A1 (en) * | 2003-07-09 | 2005-05-26 | Drummond Daryl C. | Remote detection of substance delivery to cells |
US20060258576A1 (en) * | 2003-09-05 | 2006-11-16 | Licentia, Ltd | Gdnf-related neuropeptides |
DE602005018043D1 (de) * | 2004-05-17 | 2010-01-14 | Tekmira Pharmaceuticals Corp | Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung |
GB2414934A (en) * | 2004-06-11 | 2005-12-14 | Gill Steven Streatfield | Treatment of Parkinson's disease with GDNF |
-
2007
- 2007-04-25 HU HUE07761286A patent/HUE030903T2/en unknown
- 2007-04-25 BR BRPI0710800-1A patent/BRPI0710800A2/pt not_active Application Discontinuation
- 2007-04-25 JP JP2009507946A patent/JP6105187B2/ja active Active
- 2007-04-25 US US11/740,124 patent/US7922999B2/en active Active
- 2007-04-25 AU AU2007244826A patent/AU2007244826B2/en active Active
- 2007-04-25 SI SI200731906T patent/SI2019683T2/sl unknown
- 2007-04-25 ES ES07761286T patent/ES2618787T5/es active Active
- 2007-04-25 WO PCT/US2007/067423 patent/WO2007127803A2/en active Application Filing
- 2007-04-25 DK DK07761286.9T patent/DK2019683T4/da active
- 2007-04-25 EP EP07761286.9A patent/EP2019683B2/en active Active
- 2007-04-25 PT PT77612869T patent/PT2019683T/pt unknown
- 2007-04-25 PL PL07761286.9T patent/PL2019683T5/pl unknown
-
2011
- 2011-04-01 US US13/078,357 patent/US8409548B2/en active Active
-
2013
- 2013-02-28 US US13/781,174 patent/US9050299B2/en active Active
-
2014
- 2014-08-04 JP JP2014158520A patent/JP6190336B2/ja active Active
-
2015
- 2015-05-08 US US14/707,868 patent/US9724387B2/en active Active
-
2017
- 2017-08-04 US US15/669,372 patent/US20180140672A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP6190336B2 (ja) | 2017-08-30 |
EP2019683A4 (en) | 2010-08-11 |
US20150313962A1 (en) | 2015-11-05 |
ES2618787T5 (es) | 2022-10-21 |
SI2019683T1 (sl) | 2017-04-26 |
AU2007244826B2 (en) | 2013-04-11 |
PT2019683T (pt) | 2017-03-17 |
HUE030903T2 (en) | 2017-06-28 |
US9050299B2 (en) | 2015-06-09 |
SI2019683T2 (sl) | 2022-10-28 |
US20140017297A1 (en) | 2014-01-16 |
EP2019683A2 (en) | 2009-02-04 |
AU2007244826A1 (en) | 2007-11-08 |
US20180140672A1 (en) | 2018-05-24 |
JP6105187B2 (ja) | 2017-03-29 |
WO2007127803A2 (en) | 2007-11-08 |
DK2019683T3 (da) | 2017-03-20 |
US20120009245A1 (en) | 2012-01-12 |
JP2014224140A (ja) | 2014-12-04 |
JP2009535359A (ja) | 2009-10-01 |
EP2019683B1 (en) | 2016-12-14 |
ES2618787T3 (es) | 2017-06-22 |
US8409548B2 (en) | 2013-04-02 |
PL2019683T5 (pl) | 2022-12-05 |
PL2019683T3 (pl) | 2017-06-30 |
BRPI0710800A2 (pt) | 2012-01-17 |
WO2007127803A3 (en) | 2008-10-23 |
US9724387B2 (en) | 2017-08-08 |
US20070254842A1 (en) | 2007-11-01 |
US7922999B2 (en) | 2011-04-12 |
EP2019683B2 (en) | 2022-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2019683T4 (da) | Indgivelse af vækstfaktorer til behandling af CNS-lidelser | |
DK3456707T3 (da) | 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme | |
DK1874781T3 (da) | Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme | |
DK2474321T3 (da) | Sammensætninger til behandling af collagenmedierede sygdomme | |
DK2504005T3 (da) | Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme | |
DK2545939T3 (da) | Tetrahydrobiopterin til behandling af tilstande associeret med forhøjede phenylalaninniveauer | |
DK2102169T3 (da) | Indazolylamidderivater til behandling af glucocorticoidreceptormedierede forstyrrelser | |
DK2086944T3 (da) | Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater | |
ZA200806074B (en) | Compounds for the treatment of inflammatory disorders | |
IL192691A0 (en) | Hydantoin compounds for the treatment of inflammatory disorders | |
SMAP200900085A (it) | 3-imidazolil-indoli per il trattamento di malattieproliferative | |
DK2207550T3 (da) | Tetrahydroquinolinderivater til behandling af post-traumatiske stress-lidelser | |
DK2010184T3 (da) | Implatanter til behandlingen af dopamin associerede tilstande | |
DK2285808T3 (da) | Spiroindolderivater til behandling af parasitsygdomme | |
DK2209900T3 (da) | Anvendelse af bakterier til fremstillingen af bioenergi | |
DK2056842T3 (da) | Modificeret galactosylceramid til behandling af cancerøse sygdomme | |
DK1841433T3 (da) | Præparat til behandling af lidelser i centralnervesystemet | |
DK2117565T3 (da) | Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme | |
BRPI0820440A2 (pt) | Inibidores aldh-2 no tratamento de desordens psiquiátricas | |
ZA200806455B (en) | Use of 2-imidazoles for the treatment of CNS disorders | |
DK2022504T3 (da) | Salve til behandling af hæmorider | |
DK2285416T3 (da) | Konjugat til behandlingen af mesotheliom | |
DK2323686T3 (da) | Adiponectin til behandling af lungesygdom | |
DK2109449T3 (da) | Lægemiddel til behandling af endometriose | |
IL192877A0 (en) | Use of 2-imidazoles for the treatment of cns disorders |